Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Munnam Jafar"'
Autor:
Rehan Saeed, M. Chadi Alraies, Mahboob Alam, Munnam Jafar, Martin van Zyl, David L. Fischman, Hafez Mohammad Ammar Abdullah, Waqas Ullah
Publikováno v:
Cardiovascular Revascularization Medicine. 30:26-32
Background The use of warfarin in patients with atrial fibrillation (AF) and end-stage renal disease (ESRD) has been implicated with efficacy and safety concerns. Evidence on the role of direct oral anticoagulants (DOACs) in this population is limite
Autor:
Salim S. Virani, Munnam Jafar, Mahboob Alam, Salman Zahid, Faizan Ahmed, Yasar Sattar, Waqas Ullah, Muhammad Zia Khan, David L. Fischman
Publikováno v:
Cardiovascular revascularization medicine : including molecular interventions. 34
Background Patients with end-stage renal disease (ESRD) were excluded from all major trials on the safety of transcatheter aortic valve replacement (TAVR). This study aims to identify the predictors of mortality due to the rising rate of TAVR utiliza
Publikováno v:
Cureus
Falsely elevated potassium levels are common in routine laboratory tests and should be differentiated from true hyperkalemia. If the patient is inappropriately treated for hyperkalemia, the resulting hypokalemia can lead to life-threatening cardiac a
Autor:
Sohaib Roomi, Waqas Ullah, Faizan Ahmed, Soban Farooq, Usama Sadiq, Asad Chohan, Munnam Jafar, Maryum Saddique, Shristi Khanal, Robert Watson, Margot Boigon
BACKGROUND During the initial phases of the COVID-19 pandemic, there was an unfounded fervor surrounding the use of hydroxychloroquine (HCQ) and tocilizumab (TCZ); however, evidence on their efficacy and safety have been controversial. OBJECTIVE The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9964795906bc34ccb0bd713379e9df5
https://doi.org/10.2196/preprints.21758
https://doi.org/10.2196/preprints.21758
Publikováno v:
Cureus
Acute renal failure remains a significant concern in all patients with the coronavirus disease 2019 (COVID-19) infection. Management is particularly challenging in critically ill patients requiring intensive care unit (ICU) level of care. Supportive
Autor:
Smitha Narayana Gowda, Munnam Jafar, Hafez Mohammad Ammar Abdullah, M. Chadi Alraies, Waqas Ullah
Publikováno v:
Journal of the American College of Cardiology. 75:514
Warfarin is used widely in end-stage renal disease (ESRD) patients with atrial fibrillation (AF) for stroke prophylaxis but has been associated with higher bleeding rates, labile INR and skin necrosis. Apixaban has recently been approved as an altern